Bio/Pharmaceutical Contract Manufacturing – Industry Analysis of Dose Manufacturing by the Numbers: Composition, Size, Market Shares, Profitability and Outlook
PharmSource, the acknowledged authority on bio/pharmaceutical contract manufacturing, has published its 2013 annual market intelligence report analyzing the contract dose manufacturing market. This report is a required reading for CMO executives and bio/pharmaceutical sourcing and procurement professionals as well as private equity investors and anyone needing a deeper understanding of the bio/pharmaceutical contract dose manufacturing market.
FAIRFAX, VA. September 4, 2013 – In their latest Special Report, PharmSouce experts present an important expert analysis of the bio/pharmaceutical contract dose manufacturing industry. Founded on the industry’s most comprehensive database of the dose CMO industry (PharmSource’s STRATEGIC ADVANTAGE Database of Contract Service Providers), this analysis is driven by the organization’s proprietary model of the dose manufacturing industry which is continuously updated and refined. The model and assumptions are fully explained so readers can understand how the analysis and conclusions were established.
The report characterizes the bio/pharmaceutical contract dose manufacturing industry along a number of quantitative dimensions, including number and type of participants, market size, market shares of the top CMOs and profitability, and provides PharmSource’s expert outlook for the industry.
For purposes of this report, the contract dose manufacturing universe includes companies that actively promote themselves as contract manufacturers (CMOs) and produce client formulations for pharmaceuticals supplied to the highly regulated markets in North America, Europe and Japan. The contract dose manufacturing universe is defined by 195 companies headquartered primarily in North America, Europe, Japan and India.
This 27-page report includes an Executive Summary, and chapters on Industry Composition and Size, CMO Market Shares, and CMO Profitability, and concludes with a chapter on What it Means, which further assesses the implications of the conclusions for the dose CMO industry. In addition, appendices on methodology and a listing of companies included in the CMO universe as defined are included.
Who should read and study this report? The expertise and skilled analysis in this report gives important insight not available in any other source. This report is required reading for each of the following professionals: 1) CMO executives and strategic decision-makers, who will find it to be an indispensable resource for understanding the industry and a critical input for strategic planning efforts; 2) Sourcing and procurement executives in bio/pharmaceutical companies who seek insights for supplier selection and management, who will find the report a critical resource for understanding crucial components of the supply base; 3) Private equity investors, who will gain an important deeper understanding of the market and indispensable insight for identifying potential investment targets; and 4) Anyone needing a deeper understanding of the bio/pharmaceutical contract dose manufacturing market.
For a limited time, PharmSource is offering a complimentary test-drive and a 15% annual discount on PharmSource STRATEGIC ADVANTAGE to qualified companies (new subscribers only). For more information, contact PharmSource’s Customer Service Department at +1-703-383-4903,ext. 101 / firstname.lastname@example.org.